Innovative Cellular Therapeutics

Executive Summary

Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology company advancing next-generation CAR-T cell therapies for solid tumors, with a primary focus on relapsed/refractory metastatic colorectal cancer (mCRC). Founded in 2015 and headquartered in Rockville, Maryland, ICT's lead candidate, GCC19CART, is currently in Phase 1 trials. The company's proprietary platform aims to overcome the challenges of CAR-T efficacy in solid tumors through innovative receptor design and tumor microenvironment modulation. As a private company, ICT has not disclosed total funding or valuation, but its targeted approach addresses a significant unmet need in mCRC, where standard therapies are limited. Early clinical data from the ongoing Phase 1 study will be critical in demonstrating safety and preliminary efficacy, potentially positioning ICT as a unique player in the solid tumor CAR-T landscape.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 interim safety and efficacy data for GCC19CART in mCRC40% success
• Q4 2026Potential partnership or licensing agreement for GCC19CART30% success